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Abstract
Background: Epithelial–myoepithelial carcinomas make up less than 0.1% of head and neck malignancies and are regarded
as rare, low-grade malignant neoplasms of the salivary gland. They are thought to arise from intercalated ducts with
histopathology showing a classic biphasic morphology of an outer layer of myoepithelial cells and inner layer of epithelial
cells. These tumors most commonly occur in the parotid gland; however, rare cases have also been described in the nasal
cavity, nasopharynx, subglottis, base of tongue, and the lacrimal gland.
Objective: To describe the clinical presentation, surgical management, and histopathology of the first reported case of
lacrimal sac epithelial–myoepithelial carcinoma. To conduct a literature review of this malignancy, which is present in the
lacrimal system.
Methods: Case report (n¼ 1) and literature review.
Results: We report a case of a 72-year-old man presenting with epiphora and a lacrimal sac mass with intranasal extension
on imaging and nasal endoscopy. A combined endoscopic endonasal and open approach provided successful definitive
treatment for final pathologic diagnosis of epithelial–myoepithelial carcinoma of the lacrimal sac, with orbital reconstruction
and lacrimal stenting providing good cosmetic and functional results.
Conclusions: After PubMed database search for any case series or reports of lacrimal system epithelial–myoepithelial
carcinomas, we believe this is the first documented case originating from the lacrimal sac. Although the histopathology of this
tumor is distinct, unusual location and clinical presentation may pose significant diagnostic difficulties.
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Introduction
Epithelial–myoepithelial carcinoma (EMC) is a rare,
malignant neoplasm of the salivary gland thought to
arise from intercalated ducts. First describing the
tumor in 1972, Donath et al. reported that the histopa-
thology of EMC was distinguished by its biphasic
morphology, characterized by an inner layer of
epithelial-lined ducts surrounded by an outer layer of
clear myoepithelial cells.1,2 These neoplasms make up
less than 0.1% of head and neck malignancies, account-
ing for approximately 1% of salivary gland tumors.2,3
EMCs predominantly occur in the parotid gland, fol-
lowed by the submandibular and minor salivary
glands; however, those originating from the nasal
cavity, nasopharynx, paranasal sinuses, lacrimal gland,
and several others sites have also been described.4–5
EMC is exceptionally rare in the lacrimal system, with
only 8 documented cases in the literature, all presenting
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within the lacrimal gland.6–13 There have been no docu-
mented cases of EMC originating from within the lacri-
mal sac. Although this neoplasm is known to behave like
a low-grade malignancy in the salivary gland with a
favorable survival rates, its disposition in the lacrimal
system is less clear. In this article, the authors describe
the first documented case of EMC originating from the
lacrimal sac and present a comprehensive review of lac-
rimal system EMCs reported in the literature.
Case Report
A 72-year-old Caucasian male was referred to our rhi-
nology clinic for evaluation and management of a right
lacrimal sac mass discovered incidentally on imaging.
Previously, a right-sided dacryocystorhinostomy
(DCR) had been performed by an outside ophthalmol-
ogist 8 years prior for epiphora, which was thought to be
secondary to idiopathic nasolacrimal duct (NLD)
obstruction. The surgeon reported that a mass was not
appreciated during the initial surgery, so a biopsy was
not performed. The patient’s epiphora resolved for 4
years. His medical history was also significant for
colon cancer managed by surgical resection followed
by chemotherapy 6 years ago.
In the last few months, he had undergone an extensive
work-up of his lung nodules, which unfortunately
revealed biopsy-proven recurrence of his colon cancer
with metastases to the lungs. The positron emission
tomography/computed tomography (PET/CT) obtained
during this process showed an incidental F-fluorodeoxy-
glucose-avid (FDG) right lacrimal sac mass with exten-
sion into the nasal cavity. Patient was referred to an
outside otolaryngologist who performed a right maxillary
antrostomy, partial ethmoidectomy, and biopsy of the
nasolacrimal mass. Outside evaluation of final pathology
initially was consistent with a diagnosis of oncocytoma.
A noncontrasted CT maxillofacial scan was obtained
prior to our consultation, exhibiting a soft tissue mass of
the right lacrimal sac measuring 2.1 1.6 2.4 cm (ante-
roposterior, transverse, and cranial caudal). The mass
abutted but did not invade the orbit, and it extended
into the nasal cavity at the level of the right inferior
turbinate and maxillary sinus (Figure 1). There was evi-
dence of erosion of the right medial lacrimal bone as well
as edema of the right maxillary and ethmoid sinuses.
On initial presentation, the patient endorsed worsen-
ing right-sided epiphora for the past 4 years, denying
other otolaryngologic or ophthalmologic complaints
including nasal obstruction or changes in his vision.
Physical examination showed minimal proptosis along
with tearing of the right eye. Diagnostic sinonasal endos-
copy was significant for crusting along the lateral nasal
wall anterior to the maxillary antrostomy at the reported
site of previous biopsies, with irregularity of the lateral
wall mucosa suspicious for tumor involvement.
Preoperative slit lamp examination by ophthalmology
exhibited a prominent right lacrimal sac and increased
tear lake on the right.
The patient elected to proceed with surgical excision
of the neoplasm in a combined approach with both
Oculoplastics and Otolarynology. A right-sided com-
bined transcaruncular, inferior transconjunctival orbi-
totomy and dacryocystectomy with subperiosteal
dissection was performed to expose the superior portion
of the mass. The tumor was easily dissected away from
the periorbita. Next, a complete endonasal resection was
achieved by performing a right-sided medial maxillec-
tomy, anterior ethmoidectomy, inferior turbinectomy,
and a partial middle turbinectomy utilizing stereotactic
navigation.
Figure 1. Noncontrasted maxillofacial computed tomography:
(A) axial bone window, (B) axial soft tissue window, (C) sagittal
bone window, (D) sagittal soft tissue window, (E) coronal bone-
window, and (F) coronal soft tissue window. CT depicts a soft
tissue ovoid mass centered in the right nasolacrimal sac, measuring
2.1 1.6 2.4 cm. No evidence of orbital invasion, but there is
extension into the nasal cavity via the nasolacrimal duct to the
level of the inferior turbinate and maxillary sinus. Smooth bony
remodeling is evident with erosion of the medial lacrimal bone.
CT, computed tomography.
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Through endoscopic endonasal visualization, the
common canaliculus showed no evidence of tumor
involvement. After intranasal and transorbital margins
were confirmed to be negative for tumor by frozen sec-
tion pathology, Crawford tubes were placed and the
medial orbital wall was reconstructed with a silastic
implant. The patient experienced no immediate or post-
operative complications with full ocular motility, no
ectropion or entropion, and no appreciable
enophthalmos.
The gross specimen was a 4.5 4.0 0.5 cm gray-tan,
homogenous mass. Final pathology of the right nasola-
crimal mass was consistent with the diagnosis of low-
grade EMC without perineural, lymphovascular, or
bony invasion. All final margins were negative.
Microscopically, the tumor sections showed a mass com-
posed of 2-layered epithelium arranged in interconnect-
ing nests, tubules, and gland-like structures. The inner
layer was characterized by abundant eosinophilic gran-
ular cytoplasm, while the outer layer had less conspicu-
ous cytoplasm (Figures 2 and 3). The nuclei showed mild
enlargement and pleomorphism. On immunohistochem-
istry, the outer layer of myoepithelial cells was strongly
positive for smooth muscle actin (SMA), calponin, p63,
and keratin 5/6. The inner layer of epithelial cells stained
strongly for keratin 7 (Figure 4).
Since the operation, our patient has been recovering
well. He initially experienced very mild right-sided epi-
phora, which had completely resolved after 3 months at
which time the stents were removed. Physical examina-
tion and nasal endoscopy have been performed every 3
months for surveillance, with no evidence of residual
tumor or recurrence at 20 months postoperatively.
Surveillance imaging has not been performed. He has
required periodic endoscopic debridements in the area
of resection and has nearly complete remucosalization
of the lateral nasal and orbital wall surfaces. With
regard to his lung metastases, he has successfully com-
pleted gamma knife therapy with excellent results.
Discussion
This case report documents the first EMC to originate
within the lacrimal sac. Interestingly, the initial incidence
of epiphora in the patient was thought to be secondary
to idiopathic NLD obstruction. No biopsy was per-
formed by the outside surgeon during the initial DCR
because no mass was appreciated.
However, it is very reasonable to postulate that the
tumor in our patient may have existed 8 years prior to
our definitive surgery and was potentially the cause of
the initial NLD obstruction. The tumor may have been
Figure 2. A, Low power: a tumor with oncocytic (eosinophilic) cytoplasm and gland-like spaces is shown. B, Higher power: gland-like
spaces with 2 layers of cells are shown.
Figure 3. A, Luminal more eosinophilic epithelial cells and myoepithelial cells with more pale cytoplasm. B, p63 staining of myoepithelial
cell components.
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very small at the time, slowly growing over the next
8 years. Fortunately, the tumor was visualized on the
PET/CT, which showed an FDG-avid mass that
prompted a biopsy.
In reviewing the literature, routine biopsy in cases for
NLD obstruction during DCR is controversial with
some publications recommending it and others only in
select cases. A recently published retrospective review by
Banks et al. found that an unsuspected neoplastic or
granulomatous cause of lacrimal obstruction was identi-
fied on intraoperative biopsy in only 0.46% of cases,
compared with 0% to 2.3% reported in the literature.14
The senior authors only perform biopsies if there is a
visible mass or thickened lacrimal sac flaps.
EMC is an uncommon malignancy in the head and
neck region and exceptionally rare within the lacrimal
system. Definitive diagnosis requires histopathologic evi-
dence of its pathognomonic biphasic morphology com-
prising of clear myoepithelial cells that surround
epithelial-lined ducts resembling intercalated ducts.1–3
It is important to understand the distinction between
EMC and another malignant salivary neoplasm called
myoepithelial carcinoma (MC), because they behave dif-
ferently. In terms of its histopathology, MC is composed
almost entirely of tumor cells with myoepithelial differ-
entiation. Unlike EMC, one-third of patients with MC
generally remain free of disease after treatment, another
one-third develop recurrences, and the remaining one-
third succumb to the disease with likely distant
metastases.6,15
In contrast, salivary gland EMCs generally have a
more favorable course, with 5- and 10- overall survival
rates of 73% to 94% and 60% to 90%. Studies have
found that approximately 30% to 40% of patients
have local recurrence, 20% have cervical lymph node
metastases, and 2.6% to 10% of patients experience
distant metastases. The mean age at presentation is
approximately 60 to 64 years, with a female predomi-
nance (1.3–2.0:1.0).2,3,15,16 Va´zquez et al. found that a
tumor size greater than 4 cm and high-grade histology
were associated with increased mortality.3 A follow-up
study of EMCs in all sites found that patients with T2,
T3, and T4 or M1 tumors had significantly shorter sur-
vival than patients with T1 or M0 tumors, respectively.16
To date, there are no comprehensive studies linking the
behavior of lacrimal system EMCs to salivary gland
EMCs.
In reviewing the literature, the authors found 8 other
cases of EMCs within the lacrimal system (Table 1).
Specifically, within this subset of patients, the age of diag-
nosis ranged from 41 to 72 years, with an average age of
62.8 years. This is comparable to the average age reported
in salivary gland EMCs, although instead of a female
predominance, there is a nearly equal number of males
to females with a slight male predominance (5:4).6–13
Most patients experienced similar progressive symp-
toms and physical examination findings which included
diplopia, proptosis, swelling, and restriction of extraoc-
ular motor movements. Decreased or blurred vision was
also reported in 5 of the 9 cases. Loss of vision is likely
due to the tumor’s mass effect on the orbit and optic
nerve as at least 2 cases reported return of vision to
baseline after treatment. Duration of symptoms ranged
from approximately 1 month to 8 years. Nearly all of the
cases reported that the tumors were painless in nature
with the exception of the one reported by Li et al.6–13
The patient in our case presentation experienced
worsening epiphora secondary to NLD obstruction
and mild proptosis, but he had no diplopia, restriction
of extraocular motor movements, diminished baseline
vision, or pain associated with the tumor. Of note,
Flam et al. reported the first case of a nasal cavity
EMC presenting as unilateral epiphora, which was locat-
ed between the inferior turbinate and the medial wall of
the maxillary sinus.4
Four of the 9 cases in the literature review arose in
the setting of a prior or existing pleomorphic adeno-
ma.8,10–12 In addition to these cases, 2 of the other
cases potentially arose from benign masses. Li et al.
reported the case of a 41-year-old female diagnosed
with EMC of the lacrimal gland who had previously
had an unknown right orbital mass removed 10 years
Figure 4. A, Smooth muscle actin staining of myoepithelial cell components. B, Keratin 7 staining of luminal epithelial components
stronger than myoepithelial component.
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ago.6 Singh et al. presented the case of 62-year-old
female who had swelling of the right orbit for 4 years
with rapid progression over the last 6 months which they
postulated could have been due to malignant change of a
benign neoplasm.7 Considering our patient required a
DCR 8 years ago, it is possible that the initial NLD
obstruction was secondary to an unrecognized mass
such as a pleomorphic adenoma or early EMC. This
review shows that EMCs in the lacrimal system can
occur either de novo or arise from malignant transfor-
mation of a benign mass.
With regard to radiological features, there was a sig-
nificant variety in the lacrimal system subset. Li et al.
demonstrated a multilobulated mass containing cystic
fluid–fluid levels on magnetic resonance imaging
(MRI).6 Goncalves et al. noted the mass was hypoin-
tense on MRI T1-weighted images, heterogeneously iso-
intense on T2-weighted images, and showed
heterogenous enhancement with gadolinium.10 On CT
imaging, Ostrowski et al. described the central areas of
calcifications within the tumor.11 Three cases had bony
involvement on CT. Along the lacrimal fossa,
Wiwatwongwana et al. described a scalloping effect,
and Singh et al. reported expansion and thinning of
the bone.7,13 Venkatesulu et al. showed enlargement of
the orbit with destruction and remodeling of the lateral
orbital wall.12 Several of the other cases reported no
bony erosion on imaging.6–10 There was a variety of het-
erogenous enhancement in all patients who had
contrasted-CT imaging.6–13 Figure 1 shows that the
EMC in our patient did not enlarge or invade the
orbit; however, it did extend into the nasal cavity
through the NLD, causing smooth bony remodeling
with erosion of the medial lacrimal bone.
In terms of histology, all cases provided evidence of
the characteristic biphasic morphology that defines the
neoplasm. A previous study identified four histologic
predictors of recurrence including margin status, lym-
phovascular invasion (LVI), tumor necrosis, and myoe-
pithelial anaplasia.17 Table 1 shows the pertinent gross
pathology, histopathology, and immunohistochemistry
of lacrimal system EMCs. Five cases had positive mar-
gins on surgical resection. In addition, 3 of the 8 cases
noted perineural invasion (PNI), while no cases
reported LVI.4–11
Immunohistochemistry studies for specific cell
markers are important adjuncts for confirming the diag-
nosis by definitively identifying the 2 distinct layers.
Excellent epithelial markers include cytokeratin AE1/
AE3 and CAM 5.2, while pankeratin is not very sensitive
or specific.Myoepithelial markers include p63, S100 pro-
tein, SMA, vimentin. Calponin and glial fibrillary acidic
protein were found to be not very sensitive myoepithelial
markers.16 Immunohistochemical analysis in our case
showed positivity for SMA, calponin, p63, and keratin
5/6 of outer myoepithelial cells and positivity for keratin
7 of inner epithelial cells.
In terms of treatment, surgical resection is the main-
stay of management.16 However, it does remain unclear
whether adjuvant radiotherapy is necessary. Older stud-
ies have postulated that radiation may be beneficial in
preventing local recurrence. In the largest series to date,
Va´zquez et al. found no additional survival benefit with
adjuvant radiation, but their study unfortunately did not
account for histologic grade or positive margins, only
tumor stage. Regardless, adjuvant radiotherapy is rou-
tinely recommended if there are positive margins.
Chemotherapy is not effective against these tumors.2
In the literature review of lacrimal system EMCs, all
studies reported primary surgical management of the
tumors, and 5 of those patients completed adjuvant
radiotherapy. Ostrowski et al. decided against radiother-
apy and managed conservatively with frequent follow-up
examinations.11 Chan et al. advised radiotherapy, but
the patient refused.9 Li et al. also recommended radia-
tion; however, they did not report whether this was com-
pleted.6 For the present case, adjuvant radiation was
decided against because of negative margin status and
low-grade histology without LVI or PNI. There were no
reports of any recurrence or metastasis in any of the
cases with follow-up periods that ranged from 3 to 36
months.6–13
The behavior of lacrimal system EMCs is difficult to
characterize because of their rarity; however, these neo-
plasms generally behave as low-grade malignancies and
occur either de novo or arise from malignant transfor-
mation of a benign mass. To the best of our knowledge,
this article describes the first case of an EMC originating
from the lacrimal sac without lacrimal gland or para-
nasal sinus involvement. This is of important clinical
relevance because diagnostic work-up and surgical
management for a lacrimal sac EMC will be significantly
different than a lacrimal gland EMC. Otolaryngologists
have a crucial role in diagnosing and managing lacrimal
sac tumors as shown in our case, whereas lacrimal gland
tumors are usually managed by Ophthalmologists alone.
Conclusions
Complete surgical excision with clear margins is the
mainstay of treatment for EMC given there is a potential
for local recurrence and metastasis. Histopathology is
required and immunohistochemistry is invaluable for
accurate diagnosis. Although the histopathology of this
tumor is distinct, unusual location and clinical presenta-
tion may pose significant diagnostic difficulties. A multi-
disciplinary approach with both Otolaryngology and
Ophthalmology teams should be considered for EMC
of the lacrimal sac.
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